Press Releases

Date Title and Summary View
Jun 28, 2016
MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015
Rockville, MD, June 28, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer as well as autoimmune disorders and infectious diseases,
Additional Formats
Jun 10, 2016
MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016)
Bispecific molecule based on DART® platform simultaneously targets B-cell antigens, CD32B and CD79B MGD010 was well tolerated at all dose levels with no serious adverse effects ROCKVILLE, Maryland, June 10, 2016 (GLOBE NEWSWIRE) --   -- MacroGenics, Inc.
Additional Formats
May 18, 2016
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer
MacroGenics licenses MGD015 to Janssen $75 Million upfront license fee paid to MacroGenics MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and Canada profit share MacroGenics may elect to co-promote in the United States Rockville, Maryland, May 18,
Additional Formats
May 11, 2016
MacroGenics to Present MGD010 Clinical Data at EULAR 2016
ROCKVILLE, Maryland, May 11, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
May 10, 2016
First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics
ROCKVILLE, Md., May 10, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART®, platform.
Additional Formats
May 04, 2016
MacroGenics Provides Update on Corporate Progress and First Quarter 2016 Financial Results
Eight molecules in clinical development, including six in immuno-oncology On track for three new IND submissions in 2016-2017 Promising pipeline of preclinical candidates shown at recent AACR meeting ROCKVILLE, Md., May 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Additional Formats
May 04, 2016
MacroGenics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Rockville, MD, May 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Apr 27, 2016
MacroGenics Announces Date of First Quarter 2016 Financial Results Conference Call
ROCKVILLE, Md., April 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 4, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call discussing the Company's
Additional Formats
Apr 19, 2016
MacroGenics Presents Data from Five Preclinical Programs at AACR Annual Meeting 2016
ROCKVILLE, Maryland, April 19, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 06, 2016
MacroGenics to Present at the 15th Annual Needham Healthcare Conference
Rockville, MD, April 06, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Mar 16, 2016
MacroGenics Announces Five Posters at AACR Annual Meeting 2016
ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Mar 07, 2016
Data from MacroGenics' Preclinical Studies of MGD009 Presented at Keystone Symposia's Antibodies as Drugs (X2) Conference
MGD009 is a bispecific DART molecule that targets B7-H3 and CD3 Redirected T-cell killing of multiple B7-H3-expressing tumor cell lines observed in vitro Dose-dependent inhibition of tumor growth and regression observed in vivo Linear PK and prolonged half-life support dosing at biweekly intervals
Additional Formats
Feb 29, 2016
MacroGenics Provides Update on Corporate Progress and 2015 Financial Results
Eight molecules in clinical development, including six in immuno-oncology  Multi-national Phase 1b/2 gastric cancer study initiated evaluating the combination of margetuximab and pembrolizumab  Strong balance sheet supports continued advancement of pipeline
Additional Formats
Feb 16, 2016
MacroGenics Announces Date of Fourth Quarter and Full Year 2015 Financial Results Conference Call
ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Feb 04, 2016
MacroGenics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Rockville, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Dec 02, 2015
MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference
ROCKVILLE, Md. , Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Nov 07, 2015
Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015
Anti-B7-H3 antibody is well-tolerated Single-agent, anti-tumor activity observed across several tumor types Initial evidence of T-cell immunomodulatory role ROCKVILLE, Md. , Nov. 07, 2015 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on
Additional Formats
Nov 05, 2015
Publication in PLOS Pathogens Shows the Potential of DART® Molecules for HIV Reservoir Elimination Strategy
Second paper published demonstrating DART molecule potential against HIV Data support HIV research contract recently awarded to MacroGenics by NIAID ROCKVILLE, Md. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering
Additional Formats
Nov 04, 2015
MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results
Bi-specific antibody leadership — fifth DART® molecule (MGD009) enters clinical testing B7-H3 franchise advances — Encouraging initial clinical results from ongoing enoblituzumab (MGA271) Phase 1 trial and regional rights regained  Recent collaboration with Merck on immuno-oncology study evaluating
Additional Formats
Nov 04, 2015
MacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md. , Nov. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Oct 28, 2015
MacroGenics Announces Date of Third Quarter 2015 Financial Results Conference Call
Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015 , the Company will release its financial results for the quarter ended September 30, 2015 . The Company's management team will host a conference call discussing the
Additional Formats
Oct 28, 2015
MacroGenics Regains European and Other Regional Rights to Enoblituzumab
Servier does not exercise option to license rights for enoblituzumab in its specified territories MacroGenics advances enoblituzumab and pursues integrated B7-H3 franchise strategy Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage
Additional Formats
Oct 22, 2015
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer

Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer

Additional Formats
Oct 13, 2015
MacroGenics Highlights Progress at 2015 R&D Day
Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trial B7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1 Proprietary immune checkpoint PD-1 x LAG-3 DART molecule (MGD013) introduced HIV DART and Trident™ tri-specific platform introduced ROCKVILLE, Md.
Additional Formats
Oct 06, 2015
MacroGenics to Host 2015 R&D Day

--Company to provide in-depth review of its antibody-based technology platforms and broad portfolio of therapeutics being developed to treat cancer, autoimmune disorders and infectious diseases

Additional Formats